SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Policy
How COVID-19 is Changing FDA Approval and Clearance Processes
The COVID-19 pandemic is changing the FDA irrevocably, resulting in a more dynamic, streamlined FDA that is more willing to embrace digital technology, according to panelists at the recent OC LIFe (Lifesciences Innovators Forum) virtual presentation, “COVID-19: Changes In FDA Approval & Clearance Processes.”
September 1, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
Study Details Which Cancer Patients are Most Susceptible to Severe Effects from COVID-19
Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.
August 31, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Bionano Genomics Acquisition Adds a CLIA-Certified Lab to its Novel Technology Platform
When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace cytogenetic tests to diagnose cancers and rare diseases.
August 31, 2020
 · 
5 min read
 · 
Gail Dutton
PEEL Therapeutics Preps IND for Prodrug Targeting Chemoresistant Tumors
A novel prodrug to combat high-risk pediatric solid tumors is being developed by PEEL Therapeutics, Inc.
August 25, 2020
 · 
5 min read
 · 
Gail Dutton
Business
SERS Assay IDs Viral Mutations Early, Providing a Heads-Up for New Outbreaks and Vaccine Designers
A novel, surface enhanced Raman spectroscopy (SERS) assay that allows viral evolution and replication to be studied inside single cells.
August 24, 2020
 · 
4 min read
 · 
Gail Dutton
Auxolytic’s Nutrient-Based Shut-Off Switch Boosts Cell Therapy Safety Without Transgenes
The process, auxotrophy, uses the engineered inability of an organism to synthesize a compound required for its survival to allow physicians to turn off a gene therapy if serious side effects develop.
August 21, 2020
 · 
4 min read
 · 
Gail Dutton
BioCapital
Novel Biological Cell Signaling Tech Enables IoT-Like Control of Cell Function in Vivo
A novel way to control biologic signaling allows cellular function to be modulated via cell phone, according to research presented at the American Chemical Society’s annual meeting Tuesday by researchers at the University of Maryland.
August 20, 2020
 · 
4 min read
 · 
Gail Dutton
Deals
CDMO M&As Eclipse CROs’ as Investors Focus on Fundamentals Amidst COVID-19
Pharmaceutical industry investors are betting on contract development and manufacturing organizations (CDMOs) this year, as they shift their focus from contract research organizations (CRO).
August 20, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Novateur Ventures: Overlooked Generic Drug Strategy May Prevent COVID-19’s Cytokine Storm
Two generic anti-inflammatory drugs typically used in asthma treatments are being proposed for use with COVID-19 because of their potential to dampen disease progression and severity.
August 19, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Study Shows Interferon Levels Could Be Biomarkers for COVID-19 Cytokine Storm
Shortly before COVID-19 patients’ conditions advance from moderate to severe, their levels of type I interferon (IFN) are present in the bloodstream drop.
August 18, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
New RDIF Website Details Russia’s COVID-19 Vaccine as Global Phase III Trials Begin
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
August 14, 2020
 · 
4 min read
 · 
Gail Dutton
BioMidwest
Achilles Heel of Immunotherapy-Resistant Cancers Revealed – and Eliminated – in Early Studies
Just-published research in Cell outlines a way to make even immunotherapy-resistant cancers treatable.
August 12, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
Veru’s Compound Shows Promise as Antiviral/Anti-Inflammatory Therapeutic for COVID-19
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe COVID-19 infections.
August 11, 2020
 · 
4 min read
 · 
Gail Dutton
Biotech Bay
GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising.
August 10, 2020
 · 
4 min read
 · 
Gail Dutton
Genetown
Vigeo’s Tumor Microenvironment Platform Expands Indications and Combo Therapy Possibilities
Vigeo Therapeutics is expanding indications for its tumor microenvironment (TME)-targeting oncology platform, which inhibits tumor growth by reprogramming normal cells that were recruited and coopted by a tumor.
August 7, 2020
 · 
5 min read
 · 
Gail Dutton
Load More